- Home
- INKT vs LSTA Comparison
INKT vs LSTA Comparison
Compare INKT & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INKT | LSTA |
|---|---|---|
| Founded | 2017 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 16.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | INKT | LSTA |
|---|---|---|
| Price | $12.62 | $2.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $35.00 | $23.50 |
| AVG Volume (30 Days) | 19.0K | ★ 31.7K |
| Earning Date | 11-14-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.56 | $1.81 |
| 52 Week High | $76.00 | $4.20 |
Technical Indicators
Market Signals| Indicator | INKT | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 56.82 |
| Support Level | $10.88 | $1.84 |
| Resistance Level | $12.31 | $2.02 |
| Average True Range (ATR) | 0.58 | 0.12 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 86.14 | 80.56 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.